Clovis Oncology (CLVS) Rating Lowered to Sell at BidaskClub

Clovis Oncology (NASDAQ:CLVS) was downgraded by analysts at BidaskClub from a “hold” rating to a “sell” rating in a note issued to investors on Thursday.

Several other research firms have also recently weighed in on CLVS. Cann reissued a “hold” rating on shares of Clovis Oncology in a research report on Sunday, April 8th. ValuEngine raised Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Friday, December 29th. Barclays set a $85.00 price objective on Clovis Oncology and gave the company a “buy” rating in a research report on Tuesday, February 27th. Zacks Investment Research raised Clovis Oncology from a “sell” rating to a “hold” rating in a research report on Wednesday, February 21st. Finally, Stifel Nicolaus reduced their price objective on Clovis Oncology from $125.00 to $110.00 and set a “buy” rating for the company in a research report on Tuesday, February 27th. Two investment analysts have rated the stock with a sell rating, five have assigned a hold rating and thirteen have given a buy rating to the stock. The company has a consensus rating of “Buy” and a consensus target price of $87.60.

How to Become a New Pot Stock Millionaire

CLVS opened at $50.17 on Thursday. Clovis Oncology has a 1-year low of $45.42 and a 1-year high of $99.45. The company has a debt-to-equity ratio of 0.77, a quick ratio of 7.35 and a current ratio of 7.69.

Clovis Oncology (NASDAQ:CLVS) last posted its quarterly earnings data on Monday, February 26th. The biopharmaceutical company reported ($1.04) earnings per share for the quarter, beating the consensus estimate of ($1.29) by $0.25. Clovis Oncology had a negative return on equity of 81.34% and a negative net margin of 624.02%. The company had revenue of $17.04 million during the quarter, compared to analysts’ expectations of $19.42 million. During the same period in the prior year, the business earned ($1.83) earnings per share. Clovis Oncology’s revenue for the quarter was up 21746.2% compared to the same quarter last year. equities research analysts anticipate that Clovis Oncology will post -4.81 EPS for the current fiscal year.

In related news, Director Thorlef Spickschen sold 4,500 shares of the firm’s stock in a transaction on Thursday, February 22nd. The stock was sold at an average price of $60.00, for a total value of $270,000.00. Following the completion of the transaction, the director now directly owns 16,618 shares of the company’s stock, valued at $997,080. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, insider Gillian C. Ivers-Read sold 3,000 shares of the firm’s stock in a transaction on Thursday, February 15th. The stock was sold at an average price of $54.09, for a total value of $162,270.00. Following the completion of the transaction, the insider now directly owns 180,571 shares of the company’s stock, valued at $9,767,085.39. The disclosure for this sale can be found here. Over the last ninety days, insiders sold 16,500 shares of company stock valued at $978,975. 12.50% of the stock is owned by company insiders.

Hedge funds have recently modified their holdings of the stock. Legal & General Group Plc raised its stake in Clovis Oncology by 14.5% during the third quarter. Legal & General Group Plc now owns 17,962 shares of the biopharmaceutical company’s stock worth $1,476,000 after acquiring an additional 2,269 shares in the last quarter. Schwab Charles Investment Management Inc. raised its stake in Clovis Oncology by 10.7% during the third quarter. Schwab Charles Investment Management Inc. now owns 209,894 shares of the biopharmaceutical company’s stock worth $17,296,000 after acquiring an additional 20,267 shares in the last quarter. Dimensional Fund Advisors LP raised its stake in Clovis Oncology by 62.4% during the third quarter. Dimensional Fund Advisors LP now owns 40,391 shares of the biopharmaceutical company’s stock worth $3,328,000 after acquiring an additional 15,525 shares in the last quarter. Janney Montgomery Scott LLC acquired a new position in Clovis Oncology during the third quarter worth $638,000. Finally, California Public Employees Retirement System raised its stake in Clovis Oncology by 11.7% during the third quarter. California Public Employees Retirement System now owns 33,384 shares of the biopharmaceutical company’s stock worth $2,751,000 after acquiring an additional 3,484 shares in the last quarter.

COPYRIGHT VIOLATION NOTICE: “Clovis Oncology (CLVS) Rating Lowered to Sell at BidaskClub” was published by Week Herald and is the property of of Week Herald. If you are accessing this story on another website, it was illegally stolen and republished in violation of US & international copyright and trademark law. The correct version of this story can be read at https://weekherald.com/2018/04/21/clovis-oncology-clvs-rating-lowered-to-sell-at-bidaskclub.html.

Clovis Oncology Company Profile

Clovis Oncology, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing anti-cancer agents in the United States, Europe, and internationally. Its commercial product includes Rubraca (rucaparib) tablet, a small molecule poly ADP-ribose polymerase inhibitor, used as monotherapy for the treatment of patients with deleterious BRCA mutation associated advanced ovarian cancer, who have been treated with two or more chemotherapies, and selected for therapy by an FDA-approved companion diagnostic for Rubraca.

Analyst Recommendations for Clovis Oncology (NASDAQ:CLVS)

Receive News & Ratings for Clovis Oncology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clovis Oncology and related companies with MarketBeat.com's FREE daily email newsletter.

Leave a Reply